Posted on January 13th, 2011 by Health News
A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
Read more
Filed under: Pharmacy News
Tags: cancer, Drug, Pharmacy, Tumor
Related posts
- ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors (0)
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.
Read [...]
- What Protein And Where It Is Located Are Important For Drug Design (0)
Drugs that target a single signaling pathway that drives tumor development and/or progression have been developed successfully to treat a few forms of cancer. However, in many cases drugs designed using this approach have not worked. Dario Altieri and colleagues, at the University of Massachusetts Medical School, Worcester, have now addressed this issue by using [...]
- Two-target approach may effectively stop pancreatic cancer metastasis (0)
Simultaneous targeting of two different molecules in cancer is an effective way to shrink tumors, block invasion, and stop metastasis, scientists at the University of California, San Francisco (UCSF) have found—work that may improve the effectiveness of combination treatments that include drugs like Avastin.
Read more
[tags] Pharmacy News [/tags]
- Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients (0)
In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.
Read more
[tags] Pharmacy News [/tags]
- TGen licenses ONCO-101 cancer drug to Syracuse (0)
The Translational Genomics Research Institute has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.
Read more
[tags] Pharmacy News [/tags]
Leave a Reply